Migraines remain one of the most debilitating neurological disorders, affecting millions globally. For years, sufferers have struggled with intermittent relief, leading to a cycle of dependency on acute medications and escalating headaches. Now, with advancements in preventive treatments, like eptinezumab, there is renewed hope. H. Lundbeck A/S, a champion in neurological research, is spearheading efforts to shift the paradigm in migraine management. At the 2025 International Headache Congress (IHC), they unveil a series of compelling findings that underscore the long-term effectiveness and safety of eptinezumab for individuals grappling with chronic migraines. These revelations could significantly enhance the quality of life for countless patients worldwide.
H. Lundbeck A/S emphasized its strong commitment to addressing migraines during its presentations at the 2025 International Headache Congress. Among their highlighted works were key insights from the RESOLUTION and SUNSET trials, showcasing eptinezumab’s potential to substantially reduce migraine days over extended periods.
Noteworthy Findings from the RESOLUTION Trial
The RESOLUTION trial involved patients with chronic migraines, many of whom also experienced medication overuse headaches. Initial results from the double-blind phase showed significant improvements in migraine frequency, with nearly half the participants reducing their number of monthly migraine days by over 50%. These improvements continued throughout the open-label extension phase, reinforcing eptinezumab’s efficacy.
Insights from the SUNSET Trial in Japan
In Japan, the SUNSET trial extended the exploration of eptinezumab’s effectiveness. Participants showed sustained reduction in migraine days, with over a third achieving at least a 50% reduction by week 60. These results highlight eptinezumab’s consistency across different demographics and challenges.
Key inferences from these trials are as follows:
- Eptinezumab maintains significant reduction in migraine days over extended treatment periods.
- Participants demonstrated a consistent pattern of improvement, inclusive of diverse populations.
- Safety profiles of eptinezumab were favorable, suggesting low side effect risks for prolonged use.
Lundbeck’s presentations at IHC are a compelling testament to their dedication to migraine management. By focusing on preventive treatments, H. Lundbeck A/S offers promising advancements in combating chronic migraine challenges. For patients severely impacted by migraines, eptinezumab provides a potential pathway towards a more manageable life. With the trials reinforcing the importance of preventive approaches, it opens new avenues for research and adoption in migraine therapeutics.
These findings mark a pivotal step in redefining migraine management strategies. For patients seeking continuous, reliable relief, eptinezumab stands as a promising option. Additionally, ongoing research into migraine’s underlying mechanisms continues to innovate in this vital field, paving the way for enhanced patient outcomes. As such, understanding the chronic nature of migraines and addressing it preemptively could alleviate both economic burden and personal distress caused by the condition.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
